Reviva Pharmaceuticals Holdings, Inc. · NASDAQ:RVPH
Reviva Pharmaceuticals — Investor Presentation (March 2021)
23 slides from Reviva Pharmaceuticals's investor presentation, Mar 4, 2021
Slide 1: Corporate Presentation March 2021
o~ a Y * Reviva Pharmaceuticals Holdings, Inc. yw Nasdaq (RVPH) Corporate Presentation March 2021
Slide 2: Forward Looking Statements
Forward Looking Statements ‘This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securties Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, development and clinical trial pla
Slide 3: Investment Highlights
Investment Highlights Company + Clinical-stage pharmaceutical company developing therapies for central nervous system, Gotten cardiovascular, metabolic, and inflammatory diseases + Extensive clinical pipeline with lead program in schizophrenia ready for Phase 3 Lead Asset: — Orphan Drug Designation
Slide 4: Experienced Leadership Team
Experienced Leadership Team Proven track record in Biotechnology and Pharmaceutical Development Ginny BRY Berkely UCSF alums GBD kU SONY. ‘tletl. so Wyeth ~ Sony tiovecmnotoay inc = CI SCO. a saint?
Slide 5: Extensive Clinical Development Pipeline
Extensive Clinical Development Pipeline DevelopmentPhase NCE Target (Program) Indications ‘Dacovery _Precinicl Phesel Phase Phase @RP1208 @ RPSO63
Slide 6: Dysfunctional serotonin signaling causes neuropsychiatric disorders and lung diseases
Dysfunctional serotonin signaling causes neuropsychiatric disorders and lung diseases PAH and IPF Disease/Disorder Dysfunctional dopamine and serotonin receptor signaling in the brain is implicated in the pathogenesis of schizophrenia and other neuropsychiatric disorders Psychosis Depression Dementi
Slide 7: Addressing significant unmet medical needs
Addressing significant unmet medical needs Neuropsychiatric Programs Pulmonary Programs Pulmonary Arterial Hypertension (PAH) {A Grand ViewResarch, Ine, 2017 [3 Depression: Aled Market Reseach 2018 5. PAHLCredence Research, 2018 7 2 Bipolar Disorder: Market Data Forecast 20204, ADHD: Gran View Resea
Slide 8: Neuropsychiatric Programs
viva TPRARMACEUTICALS Neuropsychiatric Programs Schizophrenia | Bipolar Disorder | Major Depressive Disorder | ADHD
Slide 9: No therapies that adequately address symptoms of schizophrenia
No therapies that adequately address symptoms of schizophrenia Schizophrenia affects ~1% of the world’s population and ~3.5 million people in the US. Yet there are currently no therapies that adequately address the complex mix of positive & negative symptoms, mood, and cognitive impairment associate
Slide 10: Multimodal modulator of serotonin and dopamine receptors
RP5063: Multimodal modulator of serotonin and dopamine receptors RP5063 modulates receptor signaling RP5063 has high affinity & selectivity RP5063 has a broad in vitro pharmacology profile RP5063 pharmacologically differs from other against key dopamine (D) and serotonin (5-HT) antipsychoties throug
Slide 11: Phase 2 trial in schizophrenia
RP5063: Phase 2 trial in schizophrenia Day Randomized, double-blind, placebo-controlled, multicenter (USA, EU, Asia) trial to assess the safety and efficacy of RP5063 in subjects with acute exacerbation of schizophrenia or schizoaffective disorder Reductionin total PANSS at the we tend of treatmenti
Slide 12: Statistically significant treatment difference from placebo
RP5063: Statistically significant treatment difference from placebo Efficacy Data for Schizophrenia PANSS Total, Change from Baseline 45 -* Placebo “-15mg 30mg =50mg * Least Squares Mean #SE Baseline Day4 ay8 Day15 Day22 Day28 EOT MVRM Analysis; Full Dataset Ge eens =
Slide 13: Mitigated positive & negative symptoms, improved prosocial functioning
RP5063: Mitigated positive & negative symptoms, improved prosocial functioning Decrease in Positive Symptoms (PANSS) PANSS Positive, Change from Baling east Sues a 5 a ta Seapine 07, 88 189 Decrease in Negative Symptoms (PANSS) PANSS Hepat, Change Kom Basing eon Sqn ean 8 Improvement in Social Funct
Slide 14: Clean side effect profile
RP5063: Clean side effect profile Neuroleptic, Endocrine and Metabolic Side Effects Comparable to Placebo CNS /Neuroleptic Side Effects Endocrine Side Effects Extrapyramidal Side Effect (%) Akathisia (%) Changein Prolactin(mIU/L) — Changein Thyroid-T4(pmol/L) : 1 3 | 2 || | l | | a ° pct tion tie HO
Slide 15: Ready for Phase 3 trial in schizophrenia
RP5063: Ready for Phase 3 trial in schizophrenia + Patients diagnosed with stable schizophrenia (Phase 1B) and healthy subjects (Phase 1A) + Welltolerated, no dose- limiting safety signals + Decrease in positive symptoms and improvement in cognition after 10 days (Phase 1B) Patients diagnosed with a
Slide 16: Pulmonary Programs
viva TPRARMACEUTICALS Pulmonary Programs Pulmonary Arterial Hypertension (PAH) | Idiopathic Pulmonary Fibrosis (IPF) 6
Slide 17: Potential to delay PAH & IPF disease progression
RP5063: Potential to delay PAH & IPF disease progression PAH & IPF are Orphan Diseases that involve dysfunctional signaling of serotoni signaling + Both PAH & IPF are rare, chronic, and debiitating conditions with no therapies that significantly delay disease progression + Patients with PAH & IPF ex
Slide 18: Preclinical data for PAH in translational models
RP5063: Preclinical data for PAH in translational models RP5063 both alone & co-administered ane HOT On PAT standard of care for PAH s 05 + RP5063 demonstrated encouraging results for PAH in (san both MCT and Sugen-Hypoxia rodent models + Mitigated PAH + Decreased respiratory resistance & restored b
Slide 19: Preclinical data for IPF in translational model
RP5063: Preclinical data for IPF in translational model RP5063 both alone & co-administered RP5063 mitigates lung fibrosis/collagen standard of care for IPF (Decrease in Hydroxyproline) + P5063 demonstrated encouraging results for IPF 2000 bleomycin-induced IPF rodent model : + Mitigated lung fibros
Slide 20: Improves survival rate in IPF
RP5063: Improves survival rate in IPF Bleomycin (BLM) Induced IPF Rodent Model Mitigates Respiratory : Resistance Improves Oxygen Saturation Improves Survival Rate 100 x0 aeee “gp =<0.05 . 9s Pi g +201 . ds * 2° z,, % z fe — 2 2 3 = son ° £1 a® am ax 6 » poss 295% = ° . a 6 oy a %, % ee Days after B
Slide 21: Ready for Phase 2 trials in PAH & IPF
RP5063: Ready for Phase 2 trials in PAH & IPF Be RP5063 Phase 2 trials in PAH and IPF viva Preclinical evidence supports the use of RP5063 in PAH and IPF Generally well-tolerated in clinical studies for schizophrenia in >250 patients Completed long-term regulatory toxicology studies Manufactured API
Slide 22: Investment Highlights
Investment Highlights Company + Clinical-stage pharmaceutical company developing therapies for central nervous system, Gotten cardiovascular, metabolic, and inflammatory diseases + Extensive clinical pipeline with lead program in schizophrenia ready for Phase 3 Lead Asset: — Orphan Drug Designation
Slide 23: Thank You
Thank You Global Operations General Inquiries Investor Relations Contact |Advisors, LLC U.S. Headquarters Reviva a
Reviva Pharmaceuticals Holdings — Investor Presentation (March 2021) on 6ix